Wu Alan H B
Department of Pathology and Laboratory Medicine, Hartford Hospital, Hartford, CT, USA.
MLO Med Lab Obs. 2003 Jun;35(6):36-8, 40.
Ischemia-modified albumin is the first biomarker for myocardial ischemia to be approved by the FDA. Other markers are being evaluated such as free fatty acids, pregnancy-associated plasma protein-A, glycogen phosphorylase isoenzyme BB, sphingosine-1-phosphate and whole blood choline. This area of clinical research will continue to grow, given the importance of detecting myocardial ischemia. Which marker or combination of markers will, ultimately, be the best approach awaits further research.
缺血修饰白蛋白是首个获美国食品药品监督管理局批准的用于心肌缺血的生物标志物。其他标志物正在接受评估，如游离脂肪酸、妊娠相关血浆蛋白-A、糖原磷酸化酶同工酶BB、1-磷酸鞘氨醇和全血胆碱。鉴于检测心肌缺血的重要性，这一临床研究领域将持续发展。最终哪种标志物或标志物组合将成为最佳方法有待进一步研究。
Zotero 插件